Ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE clinical trials
Its developmentBy Lumos Pharma, step by step2 company-led studies, furthest phase 1: when each phase was reached, its deals, target and what is ahead.How each study uses ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 2 · Other 1
NewLink Genetics Corporation (1) · Lumos Pharma (1) · Luke, Jason, MD (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain CancerNot yet recruitingPhase 1Lumos PharmaNCT07732413Written as NLG802 (indoximod Prodrug)How we know
- Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid TumorsWithdrawnPhase 1Luke, Jason, MDNCT05469490Written as NLG802 (indoximod Prodrug)How we know
- NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid TumorsCompletedPhase 1NewLink Genetics CorporationNCT03164603Written as NLG802How we know
Codes
What other systems call ethyl LEUCYL-1-METHYL-D-TRYPTOPHANATE · ClinicalTrials.gg INT017418
- UNII (FDA) NVJ85QZ036ETHYL LEUCYL-1-METHYL-D-TRYPTOPHANATEOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NVJ85QZ036 | ETHYL LEUCYL-1-METHYL-D-TRYPTOPHANATE | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.